JP2009531280A5 - - Google Patents

Download PDF

Info

Publication number
JP2009531280A5
JP2009531280A5 JP2008552536A JP2008552536A JP2009531280A5 JP 2009531280 A5 JP2009531280 A5 JP 2009531280A5 JP 2008552536 A JP2008552536 A JP 2008552536A JP 2008552536 A JP2008552536 A JP 2008552536A JP 2009531280 A5 JP2009531280 A5 JP 2009531280A5
Authority
JP
Japan
Prior art keywords
hydrogen
carbon atoms
compound
alkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008552536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/060832 external-priority patent/WO2007087505A2/en
Publication of JP2009531280A publication Critical patent/JP2009531280A/ja
Publication of JP2009531280A5 publication Critical patent/JP2009531280A5/ja
Withdrawn legal-status Critical Current

Links

JP2008552536A 2006-01-25 2007-01-22 代謝障害を処置するための化合物 Withdrawn JP2009531280A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76209106P 2006-01-25 2006-01-25
PCT/US2007/060832 WO2007087505A2 (en) 2006-01-25 2007-01-22 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009531280A JP2009531280A (ja) 2009-09-03
JP2009531280A5 true JP2009531280A5 (https=) 2011-01-20

Family

ID=38309905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552536A Withdrawn JP2009531280A (ja) 2006-01-25 2007-01-22 代謝障害を処置するための化合物

Country Status (5)

Country Link
US (1) US7820721B2 (https=)
EP (1) EP1976377A4 (https=)
JP (1) JP2009531280A (https=)
CA (1) CA2637375A1 (https=)
WO (1) WO2007087505A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1750758B (zh) * 2003-02-13 2012-06-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
RU2358722C2 (ru) * 2003-04-15 2009-06-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических расстройств
JP4837557B2 (ja) * 2003-04-30 2011-12-14 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
CA2651598A1 (en) * 2006-05-18 2007-11-29 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2026659A4 (en) * 2006-06-09 2010-06-30 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
WO2008022267A2 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
EP2240024A4 (en) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ActRIIB-FC 융합 단백질
AU2010315245B2 (en) * 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2216999B1 (https=) * 1972-10-10 1977-04-15 Serdex
US4350822A (en) * 1975-03-12 1982-09-21 American Cyanamid Company Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
DE3575127D1 (de) 1984-02-14 1990-02-08 Hirai Hidefumi Herstellung substituierter ungesaettigter sechsgliedriger ringverbindungen aus phenolabkoemmlingen.
DE3884825D1 (de) 1987-02-16 1993-11-18 Konishiroku Photo Ind Entwickler für lichtempfindliche lithographische Druckplatte, gemeinschaftlich verarbeitungsfähig für den Negativ-Typ und den Positiv-Typ und Entwicklerzusammensetzung für lichtempfindliches Material.
JPH0770025B2 (ja) 1987-09-16 1995-07-31 富士通株式会社 薄膜磁気ヘッドの製造方法
US4923501A (en) 1987-11-04 1990-05-08 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives, processes for their production, and herbicidal method and compositions
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
NZ231735A (en) 1988-12-23 1992-04-28 Ici Plc Alcohol/ether derivatives, preparation and pharmaceutical compositions thereof
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH04154773A (ja) 1990-10-15 1992-05-27 Green Cross Corp:The チアゾール誘導体
JPH04282345A (ja) 1991-03-11 1992-10-07 Mitsubishi Petrochem Co Ltd 光学活性化合物
WO1994005153A1 (en) 1992-09-09 1994-03-17 E.I. Du Pont De Nemours And Company Herbicidal benzene compounds
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JPH06293700A (ja) 1993-04-08 1994-10-21 Nippon Soda Co Ltd 6−クロロサリチル酸の製造法
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206658A (ja) 1994-01-12 1995-08-08 Shiseido Co Ltd 尋常性座瘡治療剤
JPH08119959A (ja) 1994-10-20 1996-05-14 Oyo Seikagaku Kenkyusho キサントン誘導体及びこれを有効成分とするモノアミン酸化酵素阻害剤
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
FR2730731B1 (fr) 1995-02-20 1997-04-04 Rhone Poulenc Chimie Procede de carboxylation d'un ether aromatique
AU4953796A (en) 1995-03-15 1996-10-02 Sanyko Company, Limited Dipeptide compounds having ahpba structure
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
CA2255858C (en) 1996-05-24 2007-09-11 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
JPH1087489A (ja) 1996-09-13 1998-04-07 Sankyo Co Ltd Ahpba構造含有ジペプチド化合物を有効成分とする医薬
US20020064847A1 (en) * 1996-10-22 2002-05-30 Daicel Chemical Industries, Ltd. Novel secondary alcohol dehydrogenase, process for preparing said enzyme, and process for preparing alcohols and ketones using said enzyme
JP2003517427A (ja) 1997-09-09 2003-05-27 メルク エンド カムパニー インコーポレーテッド 3−(ヨードフェノキシメチル)カルバペネム系抗菌剤
KR20010015639A (ko) 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
HK1052351B (en) 2000-06-28 2006-11-03 Japan Tobacco Inc. Benzothiazolyl ppar-gamma modulators
AR031126A1 (es) 2000-08-29 2003-09-10 Abbott Lab Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
CN101444496B (zh) * 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
EP1556085A4 (en) * 2002-11-01 2012-08-22 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM
CN1750758B (zh) * 2003-02-13 2012-06-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
RU2358722C2 (ru) * 2003-04-15 2009-06-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических расстройств
US7361686B2 (en) * 2003-04-22 2008-04-22 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4837557B2 (ja) * 2003-04-30 2011-12-14 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
EP1656127B1 (en) * 2003-08-20 2011-03-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Similar Documents

Publication Publication Date Title
JP2009531280A5 (https=)
JP2009528375A5 (https=)
JP2009528275A5 (https=)
JP2009537559A5 (https=)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP2006524252A5 (https=)
JP6238460B2 (ja) 脂質異常症治療剤
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
JP2010501010A5 (https=)
RU2008123000A (ru) Соединения для лечения метаболических нарушений
JP2007523155A5 (https=)
RU2010141823A (ru) Соединения и способ снижения мочевой кислоты
JP2008513499A5 (https=)
JP2009530398A5 (https=)
CN103102348B (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
RU2004105956A (ru) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
JP2005526696A5 (https=)
JP2009524686A5 (https=)
RU2006108572A (ru) Соединения для лечения метаболических нарушений
CA2502297A1 (en) Compounds for the treatment of metabolic disorders
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
JP2009528997A5 (https=)
CN104203240A (zh) 用于治疗精神疾病的伊潘立酮代谢物